FY20 new start-JW200170: CNP8 delivered topically in a tyrosine- derived fiber mat to reduce burn injury progression, speed wound closure, and mitigate scarring
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH22C0005
- Awardee
-
Neomatrix Therapeutics Inc. UEI Z9ZTKJPE92R4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $2,923,902
Award facts
- Contract value 100% obligated
- $2,923,902.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Fixed Price Level of Effort
- Place of performance
- Stony Brook, NY 11790, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,923,902 |
About this award
The Defense Health Agency awarded a $2.9 million fixed-price level of effort contract to Neomatrix Therapeutics Inc., a self-certified small disadvantaged business, on September 9, 2022, for research and development of an improved topical wound dressing. The contract, titled "CNP8 Delivered Topically in a Tyrosine-Derived Fiber Mat to Reduce Burn Injury Progression, Speed Wound Closure, and Mitigate Scarring," runs through September 8, 2026, with work being performed in Stony Brook, New York. No set-aside designation was used for this award. The project aims to develop advanced wound treatment modalities to support defense health programs and provide medical solutions for battlefield-related injuries.
Neomatrix Therapeutics Inc. brings relevant expertise to this effort, having previously conducted federally funded research on CNP8, including a Phase 1 randomized, placebo-controlled clinical study examining the compound's safety, tolerability, and pharmacokinetics in healthy adults, as well as IND-enabling studies for scalable peptide therapies focused on limiting burn conversion and accelerating wound closure. The contractor's specialized focus on biomedical research and advanced wound treatment positions it to deliver the technical innovations required to address burn injury progression and optimize patient outcomes through this Defense Health Agency-funded research initiative.
Quick answers
Who was awarded contract W81XWH22C0005?
W81XWH22C0005 was awarded to Neomatrix Therapeutics Inc. by Defense Health Agency (Department of Defense) on September 9, 2022.
How much is contract W81XWH22C0005 worth?
The government has obligated $2,923,902 on W81XWH22C0005.
Was contract W81XWH22C0005 competed?
The extent of competition for W81XWH22C0005 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award